

## Myanmar

### Support for Vaccine: Measles Rubella

**This Decision Letter sets out the Programme Terms of a Programme.**

<b>1. Country:</b>	Myanmar						
<b>2. Vaccine grant number:</b>	19-MMR-34a-X, 19-MMR-35a-Y						
<b>3. Date of Decision Letter:</b>	21 May 2019						
<b>4. Date of the Partnership Framework Agreement:</b>	4 April 2014						
<b>5. Programme title:</b>	New Vaccine Support (NVS), Measles Rubella, Follow-up campaign						
<b>6. Vaccine type:</b>	Measles Rubella						
<b>7. Requested product presentation and formulation of vaccine:</b>	Measles Rubella, 10 dose(s) per vial, LYOPHILISED						
<b>8. Programme Duration:</b>	2019						
<b>9. Programme Budget (indicative):</b>	(subject to the terms of the Partnership Framework Agreement)						
	<=2018	2019	2020	2021	2022	2023	Total <sup>2</sup>
Programme Budget (US\$)	n/a	3,248,500	-	-	-	-	3,248,500
<b>10. Vaccine introduction grant</b>	<b>Not applicable</b>						
<b>11. Product switch grant</b>	<b>Not applicable</b>						
<b>12. Indicative Annual Amounts:</b>	(subject to the terms of the Partnership Framework Agreement)						
<b>Type of supplies to be purchased with Gavi funds</b>	<b>0-2018</b>	<b>2019</b>					<b>2020</b>
Number of vaccine doses		4,989,700					-
Annual Amounts (US\$)	n/a	3,248,500					-
<b>13. Procurement agency:</b>	UNICEF. The Country shall release its co-financing payments each year to UNICEF.						
<b>14. Self-procurement:</b>	Not applicable						
<b>15. Co-financing obligations:</b>							

<sup>1</sup>This is the entire duration of the Programme.

<sup>2</sup>This is the total amount endorsed by Gavi for the entire duration of the Programme.

According to the co-financing policy, the Country falls within the group:

Preparatory transition phase

The following table summarises the co-financing payment(s) and quantity of supply that will be procured with such funds in the relevant year.

Type of supplies to be purchased with Country funds in each year	2019	2020	2021	2022	2023
Number of vaccine doses	262,700	-	-	-	-
Number of AD syringes	-	-	-	-	-
Number of re-constitution syringes	-	-	-	-	-
Number of safety boxes	-	-	-	-	-
Value of vaccine doses (US\$)	168,072	-	-	-	-
Total co-financing payments (US\$) (including freight)	171,000	-	-	-	-

**16. Operational support for catch-up campaigns:**


Year	Grant Number	Amount US\$
2019	19-MMR-35a-Y	2,602,452

**17. Additional Reporting Requirements:**

	Due dates
To prepare for the annual procurement of vaccines, Country shall submit the following information each year:	
<ul style="list-style-type: none"> <li>vaccine stock levels including buffer stock, by end of March;</li> </ul>	31 March 2019
<ul style="list-style-type: none"> <li>number of children to be vaccinated, wastage rates, any proposed changes in product, presentation or use, or minimum co-financing levels and vaccines received, by mid-May.</li> </ul>	15 May 2019
<ul style="list-style-type: none"> <li>Countries shall report the actual switch date in the first renewal request following the actual implementation.</li> </ul>	N/A
<ul style="list-style-type: none"> <li>To report on national and sub-national programmatic readiness using the WHO Readiness Assessment Tool (or equivalent) at the recommended time points</li> </ul>	Starting 15 months prior to campaign date, up to 1 week before the campaign, at the recommended time points of the tool
<ul style="list-style-type: none"> <li>To submit the Supplementary Immunisation Activity (SIA) technical report for Measles or Measles-Rubella campaign</li> </ul>	Within 3 months of end of campaign
<ul style="list-style-type: none"> <li>To submit the Post Campaign Coverage Survey report for Measles or Measles-Rubella campaign</li> </ul>	As soon as possible

In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	To be agreed with Gavi Secretariat
<b>18. Financial clarifications:</b> Country shall provide the following clarifications to Gavi*:  Not applicable  * Failure to provide the financial clarifications requested may result in Gavi withholding further disbursements.	
<b>19. Other conditions:</b> Not applicable	

Signed by,  
**On behalf of Gavi**



Hind Khatib-Othman